HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Propylene glycol review

This article was originally published in The Rose Sheet

Executive Summary

Propylene glycol is of "negligible concern for reproductive or developmental toxicity in humans" at current estimated exposure levels, National Toxicology Program Center for the Evaluation of Risks to Human Reproduction Expert Panel concludes following Feb. 11-13 meeting in Alexandria, Va. Panel recommends collection of additional research to address some data gaps in humans and says one critical data need is long-term follow up of children and pregnant women exposed to high dose propylene glycol from continuous IV infusion via medical tubing. CERHR published a draft report on propylene glycol including some dermal absorption data in December (1"The Rose Sheet" Dec. 16, 2002, p. 9)...

You may also be interested in...



Propylene Glycol Dermal Absorption Data Included In CERHR Draft Report

Dermal absorption of propylene glycol across intact skin is likely to be slow, and any dermal exposure to the ingredient "will result in systematic levels far below saturation of metabolic clearance," according to a draft report by the National Toxicology Program Center for the Evaluation of Risks to Human Reproduction

Germany's OTC Market in 2019: Stagnation Overall, Online Growth Continues

A weak cough and cold season in Germany last winter held back OTC sales growth in 2019, according to IQVIA, while the country's online pharmacy channel continued to expand. 

Stockwatch: Choppy Waters For Teva And Bausch

After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.

 

 

UsernamePublicRestriction

Register

RS011017

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel